CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 120 enrolled
Drug / intervention
Moxifloxacin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01296191
NCT01296191Phase 4Completed

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Frank A. Bucci, Jr., M.D.·interventional·Posted Feb 15, 2011·Updated Dec 22, 2020

In Brief

A Phase 4 clinical trial evaluating Moxifloxacin and besifloxacin for Cataracts. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataracts
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 15, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.4 years ago

Interventions

Moxifloxacindrug

One drop 4 times daily for 3 days and one drop the day of sample collection

besifloxacindrug

One drop 4 times daily for 3 days and one drop on day of sample collection